Back
Open Access

Hyperkalemia events in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan or sodium-glucose transport protein 2 inhibitors: a single-center experience

Session: Towards optimisation of heart failure therapies
Topic: Pharmacotherapy
Speaker: Doctor N. Bonini (Modena, IT)
Event: Heart Failure 2025

Congress Presentation

Add to my library

Like

About the speaker

Doctor Niccolo Bonini

Modena Polyclinic Modena University Hospital, Modena (Italy)
0 follower

5 more presentations in this session

Beta-blockers in patients with heart failure with reduced ejection fraction and chronic obstructive pulmonary disease: cardiovascular and respiratory outcomes

Speaker: Doctor B. Beer (Stockholm, SE)

Access
Abstract
Like
Thumbnail

Short-chain fatty acids, sodium-glucose cotransporter type 2 inhibitors, and cardiovascular benefit: a possible relationship?

Speaker: Doctor M. Cortes Garcia (Madrid, ES)

Access
Abstract
Like
Thumbnail

Age- and sex-related differences in heart failure characteristics and treatment patterns across the ejection fraction spectrum

Speaker: Doctor C. Basile (Stockholm, SE)

Access
Abstract
Like
Thumbnail

Sequencing, intensity, and discontinuation of guideline-directed medical therapy after heart failure hospitalisation in the United States: results from the EMPACE study

Speaker: Professor A. Alhamdow (DE)

Access
Abstract
Like
Thumbnail

Reducing the burden of advanced heart failure: a clinical and economical analysis of an intermittent Levosimendan programme

Speaker: Doctor D. Inacio Cazeiro (Lisbon, PT)

Access
Abstract
Like
Thumbnail

Access the full session

Towards optimisation of heart failure therapies

Speakers: Doctor N. Bonini, Doctor B. Beer, Doctor M. Cortes Garcia, Doctor C. Basile, Professor A. Alhamdow...
Access
Like
Thumbnail

About the event

Image

Heart Failure 2025

17 May - 20 May 2025

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

logo Bristol Myers Squibb Explore sponsored resources
logo Novartis Explore sponsored resources
logo Novo Nordisk Explore sponsored resources